ReNeuron (RENE.L) Exercise of Warrants
RENE.L has approved the issue of 3,333,333 Ordinary Shares at the warrant exercise price of 3p per share.
- No further warrants remain outstanding in respect of this original warrant issue.
- Application has been made for the shares to be admitted to trading on AIM and the shares will be issued, and dealings are expected to commence, on 3/28/1212.
- Following the issue, the number of shares in issue, including shares issued under its block-listing facility, will increase to 623,215,300.
The Bottom Line: The issued ordinary share capital of RENE.L) following this allotment consists of 623,215,300 shares with voting rights attached (one vote per Share). There are no shares held in treasury. There has been no monetary amount motioned so far. ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron’s lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. RENE.L is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina. RENE.L has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research. RENE’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.